Holen Sie sich die Stockscreener-App
6.22
1.27%
-0.08
Vorhandelsmarkt:
6.18
-0.04
-0.64%
Schlusskurs vom Vortag:
$6.30
Offen:
$6.44
24-Stunden-Volumen:
102.64K
Relative Volume:
0.03
Marktkapitalisierung:
$42.68M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
-0.1939
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
+4.54%
1M Leistung:
+74.72%
6M Leistung:
+1,041%
1J Leistung:
+902.74%
1-Tages-Spanne:
$6.195
$6.58
1-Wochen-Bereich:
$5.50
$6.6499
52-Wochen-Spanne:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
6.22 | 42.68M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV - Benzinga
Plus Therapeutics (PSTV) price target decreased by 72.34% to 38.76 - MSN
Plus Therapeutics, Inc. Income Statement – GETTEX:XMP1 - TradingView
Plus Therapeutics regains compliance with Nasdaq - MSN
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Yahoo Finance
Plus Therapeutics announces 1-for-25 reverse stock split - MSN
Why is Plus Therapeutics stock gaining Friday? - MSN
symbol__ Stock Quote Price and Forecast - CNN
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
PSTV Should I Buy - Intellectia AI
Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx - Contract Pharma
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - The Manila Times
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ - ChartMill
PSTV (PLUS THERAPEUTICS Inc.) reports wider than expected Q4 2025 loss but gains 7.39 percent on optimistic investor outlook.Earnings Surprise - Xã Thanh Hà
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus Therapeutics (PSTV) CDO receives new options and RSU grants - Stock Titan
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split - The Globe and Mail
PSTV Financials: Income Statement, Balance Sheet & Cash Flow | Plus Therapeutics Inc - Stock Titan
Plus Therapeutics (PSTV) CDO reports no common stock ownership - Stock Titan
Plus Therapeutics | 8-K: Current report - Moomoo
Plus Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement for CNS Cancer Therapies 1 - Minichart
Plus Therapeutics (PSTV) Meets Nasdaq Bid Price Requirement - GuruFocus
Plus Therapeutics regains Nasdaq compliance after one-for-25 reverse split - TradingView
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):